As of 3:59pm ET
| 0.00 / 0.00%|
The 2 analysts offering 12-month price forecasts for Aviragen Therapeutics Inc have a median target of 5.50, with a high estimate of 6.00 and a low estimate of 5.00. The median estimate represents a +301.46% increase from the last price of 1.37.
The current consensus among 2 polled investment analysts is to Buy stock in Aviragen Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.